146 related articles for article (PubMed ID: 24905400)
21. Poly(ortho ester) nanoparticles targeted for chronic intraocular diseases: ocular safety and localization after intravitreal injection.
Li H; Palamoor M; Jablonski MM
Nanotoxicology; 2016 Oct; 10(8):1152-9. PubMed ID: 27108911
[TBL] [Abstract][Full Text] [Related]
22. Development and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment.
Esteruelas G; Halbaut L; García-Torra V; Espina M; Cano A; Ettcheto M; Camins A; Souto EB; Luisa García M; Sánchez-López E
Int J Pharm; 2022 Jan; 612():121379. PubMed ID: 34915146
[TBL] [Abstract][Full Text] [Related]
23. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration.
Amrite AC; Edelhauser HF; Singh SR; Kompella UB
Mol Vis; 2008 Jan; 14():150-60. PubMed ID: 18334929
[TBL] [Abstract][Full Text] [Related]
24. Brinzolamide loaded core-shell nanoparticles for enhanced coronial penetration in the treatment of glaucoma.
Song J; Zhang Z
J Appl Biomater Funct Mater; 2020; 18():2280800020942712. PubMed ID: 33151769
[TBL] [Abstract][Full Text] [Related]
25. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
Huang X; Chau Y
Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
[TBL] [Abstract][Full Text] [Related]
26. Ocular tissue distribution and pharmacokinetic study of a small 13kDa domain antibody after intravitreal, subconjuctival and eye drop administration in rabbits.
Gough G; Szapacs M; Shah T; Clements P; Struble C; Wilson R
Exp Eye Res; 2018 Feb; 167():14-17. PubMed ID: 29074387
[TBL] [Abstract][Full Text] [Related]
27. Topical non-invasive gene delivery using gemini nanoparticles in interferon-gamma-deficient mice.
Badea I; Wettig S; Verrall R; Foldvari M
Eur J Pharm Biopharm; 2007 Mar; 65(3):414-22. PubMed ID: 17292593
[TBL] [Abstract][Full Text] [Related]
28. Investigating impacts of surface charge on intraocular distribution of intravitreal lipid nanoparticles.
Huang X; Chau Y
Exp Eye Res; 2019 Sep; 186():107711. PubMed ID: 31238078
[TBL] [Abstract][Full Text] [Related]
29. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
[TBL] [Abstract][Full Text] [Related]
30. Ocular application of nerve growth factor protects degenerating retinal ganglion cells in a rat model of glaucoma.
Colafrancesco V; Parisi V; Sposato V; Rossi S; Russo MA; Coassin M; Lambiase A; Aloe L
J Glaucoma; 2011 Feb; 20(2):100-8. PubMed ID: 20436364
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model.
Martin KR; Quigley HA; Zack DJ; Levkovitch-Verbin H; Kielczewski J; Valenta D; Baumrind L; Pease ME; Klein RL; Hauswirth WW
Invest Ophthalmol Vis Sci; 2003 Oct; 44(10):4357-65. PubMed ID: 14507880
[TBL] [Abstract][Full Text] [Related]
32. Application of lipid nanoparticles to ocular drug delivery.
Battaglia L; Serpe L; Foglietta F; Muntoni E; Gallarate M; Del Pozo Rodriguez A; Solinis MA
Expert Opin Drug Deliv; 2016 Dec; 13(12):1743-1757. PubMed ID: 27291069
[TBL] [Abstract][Full Text] [Related]
33. Distribution of Gold Nanoparticles in the Anterior Chamber of the Eye after Intracameral Injection for Glaucoma Therapy.
Sonntag T; Froemel F; Stamer WD; Ohlmann A; Fuchshofer R; Breunig M
Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34204364
[TBL] [Abstract][Full Text] [Related]
34. Transplantation of Retinal Ganglion Cells Derived from Male Germline Stem Cell as a Potential Treatment to Glaucoma.
Suen HC; Qian Y; Liao J; Luk CS; Lee WT; Ng JKW; Chan TTH; Hou HW; Li I; Li K; Chan WY; Feng B; Gao L; Jiang X; Liu YH; Rudd JA; Hobbs R; Qi H; Ng TK; Mak HK; Leung KS; Lee TL
Stem Cells Dev; 2019 Oct; 28(20):1365-1375. PubMed ID: 31580778
[TBL] [Abstract][Full Text] [Related]
35. [A challenge to primary open-angle glaucoma including normal-pressure. Clinical problems and their scientific solution].
Sugiyama K
Nippon Ganka Gakkai Zasshi; 2012 Mar; 116(3):233-67; discussion 268. PubMed ID: 22568103
[TBL] [Abstract][Full Text] [Related]
36. Gene delivery to the eye using adeno-associated viral vectors.
Martin KR; Klein RL; Quigley HA
Methods; 2002 Oct; 28(2):267-75. PubMed ID: 12413426
[TBL] [Abstract][Full Text] [Related]
37. Studies on lactoferrin nanoparticles of gambogic acid for oral delivery.
Zhang ZH; Wang XP; Ayman WY; Munyendo WL; Lv HX; Zhou JP
Drug Deliv; 2013 Feb; 20(2):86-93. PubMed ID: 23495734
[TBL] [Abstract][Full Text] [Related]
38. The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery.
Wen Z; Muratomi N; Huang W; Huang L; Ren J; Yang J; Persaud Y; Loloi J; Mallangada N; Kung P; Honkanen R; Rigas B
Int J Pharm; 2019 Feb; 557():273-279. PubMed ID: 30597269
[TBL] [Abstract][Full Text] [Related]
39. Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma.
Sánchez-López E; Egea MA; Davis BM; Guo L; Espina M; Silva AM; Calpena AC; Souto EMB; Ravindran N; Ettcheto M; Camins A; García ML; Cordeiro MF
Small; 2018 Jan; 14(2):. PubMed ID: 29154484
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
Nomoto H; Shiraga F; Kuno N; Kimura E; Fujii S; Shinomiya K; Nugent AK; Hirooka K; Baba T
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
